ClinicalTrials.gg
Active, not recruitingNCT07614997Updated Nov 18, 2026

Effectiveness and Safety of the Ulthera® System for Skin Laxity in the Lower Face, Submentum and Neck

An interventional study of Ulthera System in Cutis Laxa, sponsored by Merz North America, Inc.. Active, not recruiting at 7 sites in China. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to demonstrate superiority of treatment with the Ulthera System compared to untreated control for the improvement of skin laxity of the lower face, submental area and neck and to demonstrate the safety of treatment with the Ulthera System for the improvement of skin laxity of the lower face, submental area and neck.

02

Conditions studied

  • Cutis Laxa

Keywords

  • Skin laxity
03

In context

Lead sponsor

Merz North America, Inc. is the lead sponsor of 53 studies on the registry; 1 is open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 19 (95%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate lower face, submental and/or neck laxity, that is amenable to improvement with non-invasive intervention and not severe enough for surgical intervention.
  • Willing to abstain from all other aesthetic treatments on ANY part of the face, submentum or neck, including but not limited to injectable fillers, implants, neurotoxin, skin peels, laser treatments, surgical treatments, etc. for the clinical investigation's duration.
  • Willing and able to refrain from chronic use of aspirin, ibuprofen, naproxen, or other nonsteroidal anti-inflammatory drugs (NSAIDs) for 10 to 14 days post-treatment.
  • Has an adequate understanding of the Chinese language.
  • Willing and able to comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Scarring in area(s) to be treated.
  • Any active implants.
  • Any metallic implants in area(s) to be treated.
  • Any open wounds or lesions, including active herpes simplex, in the area(s) to be treated.
  • Presence of an active systemic or local skin disease, including active, cystic, or severe inflammatory acne in the area(s) to be treated.
  • History of keloid formation or hypertrophic scarring.
  • History of the following cosmetic treatments in area(s) to be treated:

    • Skin-tightening procedure,
    • Injectable crosslinked hyaluronic acid (HA)/collagen temporary dermal fillers of the lower face, submentum or neck within the past 12 months.
    • Injectable non-crosslinked HA dermal fillers of the lower face, submentum or neck within the past 6 months.
    • Injectable semi-permanent/permanent facial fillers
    • Neurotoxin treatment of the lower face, submentum or neck within the past 6 months.
    • Liposuction of the lower face, submentum or neck within the last 12 months.
    • Fat grafting of the lower face, submentum or neck within the last 12 months.
    • Deoxycholic acid within the last 12 months; and/or
    • Chemical peeling or dermabrasion treatments within the past 12 months.
    • Cryolipolysis
  • Had prior surgery in the lower-facial area and/or neck/submentum or has a permanent implant or graft in the lower-facial area that could interfere with effectiveness assessments.
  • Has undergone oral surgery in the past 30 days.
  • Participants who have used isotretinoin or other retinoid medications within 6 months prior to enrollment or have applied topical retinoid-containing medications on the face or neck area within 2 weeks prior to enrollment or planning such treatments during the study period.
  • Marked facial asymmetry, deep dermal scarring, or thick sebaceous skin in the full face.
  • Severe solar elastosis.
  • Facial nerve palsy or history of facial nerve palsy.
  • Tattoos in the area(s) to be treated (excluding microblading eyebrow).
  • Current smoker or history of smoking in the last 12 months.
  • Current daily user of any nicotine-containing products
  • Is a female of childbearing potential1 and not using medically effective 2 or is pregnant, lactating, or planning to become pregnant during the clinical investigation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Treatment With Ulthera System

    Participants randomized to receive a single treatment with Ulthera system to lower face, submentum and neck on Day 1.

    Device: Ulthera System

  • Other
    Control/Delayed treatment With Ulthera System

    Participants will remain untreated until Day 90 and then receive a single treatment with Ulthera system to lower face, submentum and neck.

    Device: Ulthera System

Interventions

  • DeviceUlthera System

    Participants will receive treatment with the Ulthera system which consists of three primary components: the control unit, handpiece and interchangeable transducers.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With at Least "Improved" in Lower Face, Submental and Neck Skin Laxity on Global Aesthetic Improvement Scale as Determined by the Blinded Live Evaluator (eGAIS) at Day 90 Compared to Baseline Photographs

    Blinded live evaluator will use eGAIS to evaluate global aesthetic improvement in the facial appearance of participants. The GAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome.

    Time frame: Day 90

Secondary outcomes

  1. Three Independent, Blinded Raters GAIS (rGAIS) Score in Lower Face, Submental and Neck Skin Laxity at Day 90 Compared to Baseline Photographs

    Three independent, blinded raters will use rGAIS to evaluate global aesthetic improvement in the facial appearance of participants. The GAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome.

    Time frame: Day 90

  2. Treating Investigator's GAIS (iGAIS) Score in Lower Face, Submental and Neck Skin Laxity at Day 90 Compared to Baseline Photographs

    Treating investigators will use the iGAIS to assess overall aesthetic improvement of the lower face, submentum, and neck. The GAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome. This outcome measure is prespecified for the Treatment Group only.

    Time frame: Day 90

  3. Participant's GAIS (pGAIS) Scores in Lower Face, Submental Skin and Neck Laxity at Day 90 Compared to Baseline Photographs

    Participants will self-report using the pGAIS to assess overall aesthetic improvement of the lower face, submentum, and neck. The pGAIS is a 5-point scale (1-5), where: 1(very much improved); 2 (much improved); 3 (improved); 4 (no change); 5 (worse). Higher scores indicate a worse outcome. This outcome measure is prespecified for the Treatment Group only.

    Time frame: Day 90

07

Study locations

7 sites
  • Merz Investigative Site
    Beijing, Beijing Municipality 100034, China
  • Merz Investigative Site
    Beijing, Beijing Municipality 100730, China
  • Merz Investigative Site
    Guangzhou, Guangdong 510317, China
  • Merz Investigative Site
    Nanjing, Jiangsu 210003, China
  • Merz Investigative Site
    Xi'an, Shaanxi 710004, China
  • Merz Investigative Site
    Shanghai, Shanghai Municipality 200040, China
  • Merz Investigative Site
    Shanghai, Shanghai Municipality 200443, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
Jun 15, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07614997
Collaborators
Ulthera, Inc
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 15, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Merz Medical Expert
study director · Merz North America, Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion